BPR1K871

BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1].

Product Specifications

CAS Number

[2443767-35-7]

Product Name Alternative

DBPR114

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FLT3

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bpr1k871.html

Purity

99.12

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC(Cl)=CC=C1)NC2=NC=C(S2)CCNC3=NC=NC4=C3C=CC(OCCCN(C)C)=C4

Molecular Formula

C25H28ClN7O2S

Molecular Weight

526.05

Precautions

H302, H315, H319, H335

References & Citations

[1]Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7 (52) : 86239–86256.